Skip to Content

About the Program

The CCOPs and the MB-CCOPs are a community-based clinical trials network which brings academic investigators (through the Research Bases) together with community physicians to conduct scientifically important and clinically meaningful clinical trials that result in better care for cancer patients and persons at risk for cancer. The MB-CCOPs bring the CCOP structure to communities with greater than 30 percent minority cancer populations to facilitate the inclusion of underserved populations in the same clinical trials. More on what the Network has accomplished and where it is going can be found at:

For Patients & the Public

CCOP and MB-CCOP physicians in local medical practices partner with academic investigators working out of NCI-designated Cancer Centers and Cooperative Groups to test and validate the latest interventions against cancer.

These community physicians provide real-world implementation of the trials and subsequently, the successful therapeutic regimens are rapidly integrated into their practice of medicine.

For Potential Researchers

Now is the best time yet to become a part of this clinical trials network. Cancer research is undergoing significant changes and new genomic information is on its way to being translated into medical practice. Interested researchers and community physicians can learn more about becoming a member of the CCOP Network here. Information about Research Base participation is at the Researcher Resources page.

Top

Ben Klassen, a CCOP patient at the Florida Pediatric CCOP, is shown with his physician, Dr. Emad Salman.

Accomplishments (pdf 997kb)

With 30% of patients accrued from CCOPs and MB-CCOPs, a study looking at Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer saw an improvement in survival and reduction in early stage breast cancer recurrence. The findings were reported in 2005 of the randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol, to that of adriamycin and cyclophosphamide followed by taxol plus herceptin, in node-positive breast cancer patients who had tumors that overexpressed HER2.